Supplementary Figure S2 from Effective Antitumor Immunity Can Be Triggered by Targeting VISTA in Combination with a TLR3-Specific Adjuvant

• DOI: 10.1158/2326-6066.24709728.v1
• Publication Date: 2023-12-01T07:23:15Z
• Authors: Bo Wang; Ziwei Ou; Wenlong Zhong; Lin Huang; Wenjian Liao; Yiyu Sheng; Zhixing Guo; Junyu Chen; Wenjuan Yang; Ke Chen; Xiaodong Huang; Tenghao Yang; Tianxin Lin; Jian Huang

<p>Overall survival (OS) was analyzed with the Kaplan-Meier method stratifying 144 Cohort II UCB patients according to high or low levels of VISTA+ endothelial cells (ECs, A), or tumor cells (TCs, B)</p>